The Advisory Council on the Misuse of Drugs (ACMD) is currently reviewing the evidence of the misuse and harms of ketamine and ketamine analogues in the United Kingdom, as requested by Government. The report aims to consider the evidence regarding the current use and harms of these compounds.
The ACMD would be grateful for your written feedback by Tuesday 19th August 2025, as part of a public call for evidence. We welcome submissions of evidence from as broad a spectrum of participants as possible and would be grateful if you could please circulate this call for evidence to other colleagues and relevant stakeholders. The ACMD will use this evidence to assist in formulating advice to Government.
Thank you in advance for your assistance. If you have any questions or concerns about this call for evidence, please feel free to get in touch with us at acmd@homeoffice.gov.uk.
Completing the questionnaire
Although your expertise may be better suited to tackling only a subset of the following questions, it would be helpful if you were to consider every question in the questionnaire. Please note that you are not required to answer all questions - only those where you have relevant information, experience, or evidence to provide.
Where possible, please provide supporting evidence and references in your response. The ACMD considers a wide range of evidence as part of its advice, including published literature, statistics, data from UK organisations and expert and stakeholder opinions.
How we will use your information
Respondents should note that evidence submitted will inform the development of recommendations from the ACMD and could ultimately be published. However, in the interest of confidentiality and protecting commercial interests, any information submitted will be non-attributable.
All data submitted in response to this call for evidence will be protected by the ACMD Secretariat in accordance with the UK General Data Protection Regulation (UK GDPR). Furthermore, Section 43(1) of the Freedom of Information Act provides an exemption for information which is a trade secret, whilst Section 43(2) exempts information whose disclosure would, or would be likely to, prejudice the commercial interests of any person (an individual, a company, the public authority itself or any other legal entity).